Former cigarette smokers who vape more likely to get lung cancer: study
“Former cigarette smokers who vape are more likely to get lung cancer, warns new research. People who have stubbed out the habit but who use e-cigarettes or vaping devices are more likely to develop the deadly disease than those who don’t vape, according to the findings of the Korean study.”
Disparity of the Treatment of Unresectable Non-small Cell Lung Cancer Regarding Chemotherapy: A Systematic Review and Meta-Analysis
“This study investigates disparities in chemotherapy treatment for unresectable non-small cell lung cancer (NSCLC) between urban and rural populations. Despite advancements in NSCLC treatments enhancing survival, significant inequities persist, notably in rural areas where access to care is often limited, resulting in poorer outcomes.”
Amgen’s Imdelltra granted FDA accelerated approval to treat small cell lung cancer
“The immunotherapy has been specifically authorised for use in adults with disease progression on or after platinum-based chemotherapy.”
Emerging Biomarkers and Tumor Heterogeneity Lead the Way in Lung Cancer
“Ongoing clinical trials in small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC) are fueling excitement in the oncology community with research efforts focusing on understanding the biology and heterogeneity of SCLC, and FDA approvals in 2024 in the NSCLC setting.”
Measuring Lung Function More Accurately and More Equitably
“Removing race from equations that estimate lung function will shift the categorization of disease severity across patient populations, moving more Black individuals into an advanced disease category, according to new research led by scientists at Harvard Medical School. At the same time, more white and Hispanic people would be reclassified as having less advanced illness.”
NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC
“The FDA has granted breakthrough therapy designation to the investigational ALK-selective inhibitor NVL-655 as a treatment for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC), according to a press release from the developers, Nuvalent, Inc. Specifically, the designation supports the use of NVL-655 in patients who have received at least 2 prior lines of ALK tyrosine kinase inhibitors.”
Dr Liu Previews ASCO 2024 Lung Cancer Data
“Stephen V. Liu, MD, associate professor, medicine, Georgetown University, director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, discusses several studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of non–small cell lung cancer (NSCLC).”
Immunotherapy may boost survival after lung cancer surgery
“Immunotherapy can boost the survival of early-stage lung cancer patients eligible for surgery when it’s combined with chemotherapy, a new clinical trial reports. Those who got immunotherapy before and after surgery — along with pre-surgical chemo — had a 42% lower risk of cancer progression, recurrence or death than those who only received chemo, according to findings published Wednesday in the New England Journal of Medicine.”
Breaking bad blood: How rogue neutrophils help lung cancer spread
“Lung cancer remains a leading global health concern, responsible for the highest number of cancer-related deaths worldwide. Central to its development is the tumor microenvironment, which involves a complex interplay with immune cells such as neutrophils. Initially perceived as beneficial due to their anti-tumor activities in early cancer stages, neutrophils are now understood to play a dual role, potentially enhancing cancer metastasis under the influence of the tumor surroundings.”
